Chinese Cell And Gene Therapies Enjoy Limelight Amid Summer Fundraising Lull

 
• By Dexter Jie Yan

CorrectSequence led the pack of Chinese cell and gene therapy developers seeking new funding with a roughly $14m series A-plus round. In other modalities, antibody-focused developers Mabgeek and Novamab closed series Bs.

funding
some bright spots in summer lull for Chinese biotech financings • Source: Shutterstock

More from China

More from Focus On Asia